Game-changing HIV research offers hope for people with HIV and to end AIDS

    29-Apr-2022
|
Shobha Shukla - CNS
Contd from previous issue
Islatravir is being developed as a daily oral therapy in combination with doravirine; once-weekly oral therapy in combination with MK-8507 (a non-nucleoside reverse transcriptase inhibitor); long-acting oral and injectable treatment in combination with Lenacapavir; as well as once-monthly oral and an yearly implant for PrEP. But, as of now, FDA has placed a full or partial hold on Islatravir programmes due to some dose-related immunological concerns. A new class of drugs called maturation inhibitors-MI-254 oral and MI-937 long-acting injectable-are in various stages of clinical development. Maturation inhibitors block the protein processing in the late stage of the viral life cycle. Broadly neutralising antibodies, that became a household name during COVID-19, are also being studied for treatment and prevention. Dr Orkin minces no words regarding the future of HIV treatment: “We want choices for everyone. We need treatments that work for everyone; that are safe for everyone, including for pregnant and lactating mothers and for children; that are affordable”.